23andMe slowed by FDA order, but the company (and personalized medicine) advances

Image: U.S. Patent and Trademark Office

Genetics will be a cheap and critical part of daily life, 23andme co-founder Anne Wojcicki has told the SXSW festival, claiming that genetics should be used for preventative medicine to bring down the cost of healthcare.

Wojcicki admitted the move by the US Food and Drug Administration service in November to stop 23andMe marketing its genetic testing service had hampered the company.

“We are pioneers. We’ve had a lot of ups and downs but we have lots of tenacity to push on through. It will take time money and effort to figure out the path forward.” That path involves submitting applications that detail 23andme as a medical device, she said.

Read the full, original story: 23andMe admits FDA order ‘significantly slowed up’ new customers


Additional Resources:

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
Send this to a friend